Three-year follow-up of choroidal neovascularisation in eyes of chronic central serous chorioretinopathy
- PMID: 32051140
- DOI: 10.1136/bjophthalmol-2019-315302
Three-year follow-up of choroidal neovascularisation in eyes of chronic central serous chorioretinopathy
Abstract
Aims: This study aimed to report the 3-year follow-up results of the clinical course and structural changes of choroidal neovascularisation (CNV) by optical coherence tomography angiography (OCT-A) in eyes with a history of chronic central serous chorioretinopathy (CSC).
Methods: This is a retrospective study of patients with chronic CSC complicated with CNV. Patients were recorded of best-corrected visual acuity (BCVA) and treatment modalities. OCT was used to evaluate the presence of subretinal fluid (SRF), type of CNV, changes in central retinal thickness (CRT) and subfoveal choroidal thickness (SFCT). Changes in the size, vessel density (VD) and morphology of CNV were evaluated by OCT-A. Comparison between baseline and final parameters was made.
Results: A total of 30 eyes in 26 patients, most of whom had previous treatment for chronic CSC, were included with a mean follow-up period of 40.37±4.11 months. No changes in BCVA were noted (p=0.562). During the 3-year follow-up period with OCT-A, five eyes had SRF noted. The other 25 eyes remained SRF free throughout the course. Regarding the morphological changes, the size of CNV enlarged significantly (p<0.01); VD of CNV decreased significantly (p=0.01); and the number of CNV with visible core vessel significantly increased (p<0.01). A significant reduced SFCT was noted (p=0.02), while the CRT remained unchanged (p=0.855).
Conclusion: For most eyes infected with chronic CSC receiving previous treatment for the activity of chronic CSC, with CNV subsequently found on OCT-A, a midterm stable clinical course up to 3 years was noted, despite significant structural changes of CNV evaluated by OCT-A.
Keywords: neovascularisation.
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Similar articles
-
Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy.Br J Ophthalmol. 2020 Jul;104(7):910-916. doi: 10.1136/bjophthalmol-2019-314625. Epub 2019 Oct 15. Br J Ophthalmol. 2020. PMID: 31615761
-
Optical coherence tomography angiography findings in cystoid macular degeneration associated with central serous chorioretinopathy.Br J Ophthalmol. 2019 Nov;103(11):1615-1618. doi: 10.1136/bjophthalmol-2018-313048. Epub 2019 Jan 2. Br J Ophthalmol. 2019. PMID: 30602447
-
OCT Risk Factors for 3-Year Development of Macular Complications in Eyes With "Resolved" Chronic Central Serous Chorioretinopathy.Am J Ophthalmol. 2021 Mar;223:129-139. doi: 10.1016/j.ajo.2020.10.011. Epub 2020 Oct 22. Am J Ophthalmol. 2021. PMID: 33342759
-
Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy.Ophthalmology. 2019 Apr;126(4):576-588. doi: 10.1016/j.ophtha.2018.12.048. Epub 2019 Jan 17. Ophthalmology. 2019. PMID: 30659849
-
Comparison of microvasculature between neovascular, non-neovascular chronic central serous chorioretinopathy cases and asymptomatic fellow eyes using swept-source optical coherence tomography angiography.Int Ophthalmol. 2025 Jul 18;45(1):297. doi: 10.1007/s10792-025-03673-5. Int Ophthalmol. 2025. PMID: 40679632
Cited by
-
Applications of Multimodal Imaging in Central Serous Chorioretinopathy Evaluation.J Ophthalmol. 2021 Jul 24;2021:9929864. doi: 10.1155/2021/9929864. eCollection 2021. J Ophthalmol. 2021. PMID: 34350034 Free PMC article. Review.
-
Incidence of recurrence and development of polypoidal lesions following half-dose and two-thirds dose photodynamic therapy for pachychoroid neovasculopathy.Sci Rep. 2025 May 30;15(1):18975. doi: 10.1038/s41598-025-03782-2. Sci Rep. 2025. PMID: 40447767 Free PMC article.
-
The role of inflammation in central serous chorioretinopathy: From mechanisms to therapeutic prospects.Front Pharmacol. 2024 May 21;15:1200492. doi: 10.3389/fphar.2024.1200492. eCollection 2024. Front Pharmacol. 2024. PMID: 38835666 Free PMC article. Review.
-
3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization.Sci Rep. 2021 Jun 24;11(1):13286. doi: 10.1038/s41598-021-92693-z. Sci Rep. 2021. PMID: 34168238 Free PMC article.
-
Choroidal Response to Intravitreal Bevacizumab Injections in Treatment-Naïve Macular Neovascularization Secondary to Chronic Central Serous Chorioretinopathy.Biomedicines. 2024 Dec 3;12(12):2760. doi: 10.3390/biomedicines12122760. Biomedicines. 2024. PMID: 39767667 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous